Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib-II Study of Ramucirumab Combined With Standard Nab-paclitaxel and Gemcitabine as First-line Treatment in Patients With Advanced Pancreatic Adenocarcinoma

NCT03745430 is registered in ClinicalTrials.gov with Hellenic Cooperative Oncology Group as lead sponsor.

NCT NCT03745430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03745430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib-II Study of Ramucirumab Combined With Standard Nab-paclitaxel and Gemcitabine as First-line Treatment in Patients With Advanced Pancreatic Adenocarcinoma
Lead sponsor
Hellenic Cooperative Oncology Group
Phase
Phase 1/2
Overall status
Completed
Start date
January 29, 2019
Completion date
April 23, 2023
Enrollment
54 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma